Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM008 is a standardized Traditional Chinese Medicine (TCM) herbal formula developed primarily for the management of cancer-related fatigue (CRF) and the improvement of quality of life in cancer patients. The formula is composed of six specific medicinal herbs: Radix Astragali (Huangqi), Radix Rehmanniae (Shengdihuang), Radix Glehniae (Beishashen), Radix Ophiopogonis (Maidong), Poria (Fuling), and Radix Glycyrrhizae (Gancao). Its mechanism of action is thought to involve the modulation of inflammatory cytokines and the restoration of energy metabolism, addressing the 'Qi-Yin deficiency' pattern often observed in oncology patients. Clinical research, including Phase II trials conducted by institutions such as the University of Hong Kong, has investigated its efficacy in reducing fatigue scores and improving physical functioning in patients undergoing or following chemotherapy and radiotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MM008.